IC19/1563
- Generic Name
- IC19/1563
CD19-Directed CAR-T Cell Therapy for the Treatment of Relapsed/Refractory B Cell Malignancies
Phase 1
Recruiting
- Conditions
- Recurrent B-Cell Non-Hodgkin LymphomaRecurrent Small Lymphocytic LymphomaRefractory Transformed Chronic Lymphocytic LeukemiaRecurrent Chronic Lymphocytic LeukemiaRefractory B-Cell Non-Hodgkin LymphomaRefractory Small Lymphocytic LymphomaRecurrent Transformed Chronic Lymphocytic LeukemiaRefractory Chronic Lymphocytic Leukemia
- Interventions
- Procedure: Biospecimen CollectionProcedure: Bone Marrow AspirationProcedure: Bone Marrow BiopsyProcedure: Computed TomographyProcedure: Magnetic Resonance ImagingProcedure: Positron Emission Tomography
- First Posted Date
- 2021-05-19
- Last Posted Date
- 2024-10-14
- Lead Sponsor
- Mayo Clinic
- Target Recruit Count
- 25
- Registration Number
- NCT04892277
- Locations
- 🇺🇸
Mayo Clinic in Rochester, Rochester, Minnesota, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath